Silevertinib's 60% ORR and 15.2-month mPFS in non-classical EGFRm NSCLC hinges on FDA alignment on a pivotal path in H2 2026

Bull

A positive outcome would be FDA agreement on a single-arm accelerated approval pathway using ORR as the primary endpoint in a defined non-classical EGFR mutation cohort, consistent with precedents in other genomically selected NSCLC populations. This would allow BDTX to initiate a pivotal trial rapidly with the 150 mg QD dose already validated in Phase 2, converting the 60% ORR and 86% CNS ORR into a credible registration package and establishing silevertinib as the first approved agent purpose-built for non-classical EGFRm NSCLC.

Bear

The primary failure mode is FDA requiring a randomized confirmatory trial against an active comparator before or concurrent with any accelerated approval, which would substantially increase capital requirements, extend timelines, and strain the $118M cash runway that extends into H2 2028. A secondary risk is FDA narrowing the eligible non-classical mutation spectrum to a subset smaller than the broad population studied in Phase 2, reducing the addressable patient population and complicating trial enrollment.